2cureX continues its efforts to ensure a strong IP protection for its IndiTreat test in the United States
Press releases regulatory
2cureX AB (“2cureX”, NASDAQ: 2CUREX) is pleased to announce that a patent on the IndiTreat® test has been granted in the United States. In March 2019 2cureX communicated that the company had received Notice of Allowance on its patent application no. 15/321,888. This patent application has now been issued in full with the patent number US10,371,695.
Expanding the 2cureX patent protection for the IndiTreat Test on the US market has been a key part of the company’s long-term commercialization strategy and launch efforts beyond market introduction in 2020. As part of the IP process, similar patents have previously been issued in Europe and recently in Hong Kong.
Grith Hagel, Inventor and Head of Project Management at 2cureX says “Tailoring the right treatment for the individual cancer patient is a hot topic these days for physicians, patients and health authorities. At 2cureX’s inception back in 2006 we formulated a vision to develop a technology that could match the individual cancer patient with an effective medical treatment” and Grith Hagel continues: “our IndiTreat test is now delivering the envisioned matchmaking, and it is a pleasure to see that it is getting full patent protection also for the US market”.
“2cureX is in the midst of its pre-launch activities to pave the way for a full launch of IndiTreat in 2020” says Maarten van der Linden, Chief Business Officer and he continues; “In the discussions we have with commercial stakeholders and potential partners we’re often asked how well our technology is protected in the major markets. To complete this step in the patent protection for the US market is an important step for our company and our ongoing launch efforts.
For more information about 2cureX:
Ole Thastrup, Chief Executive Officer
Telephone: +45 22 11 53 99
Svensk Kapitalmarknadsgranskning AB
Phone: +46 11 32 30 732
2cureX has developed the IndiTreat® (Individual Treatment Design) test. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour and identifies the approved cancer treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient will be provided the selected treatment.
IndiTreat® is being clinically validated in eight clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.
IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is presently being introduced into the European market through an Early Access Program.
The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).